Click here to skip navigation

ACCME Accreditation Statement

The American Academy of Pediatrics (AAP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The AAP designates this enduring material for a maximum of 10 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The AAP designates this PI CME activity for a maximum of 20 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is approved for 30 NAPNAP CE contact hours of which 0 contain pharmacology (Rx) content, (0 related to psychopharmacology), per the National Association of Pediatric Nurse Practitioners (NAPNAP) Continuing Education Guidelines.


This Performance Improvement CME program has been reviewed and is approved for a maximum of 20.00 AAPA Category 1 PI-CME credits by the Physician Assistant Review Panel. All states of the activity must be completed for a participant to claim any credit. Approval is valid until February 25, 2017. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity. This program was planned in accordance with AAPA's CME Standards. 


This activity is acceptable for a maximum of 30 credits. These credits can be applied toward the AAP CME/CPD Award available to Fellows and Candidate Members of the AAP.

Course Goals

The goal of this EQIPP Growth Surveillance and Linear Growth Failure course is to help you create plans for improvement and to address gaps identified in key activities of clinical care related to growth surveillance and the identification of children with linear growth failure. These activities focus on improving ongoing medical care and patient/family education and support. You will collect baseline and follow-up data as you work to improve care and processes through Plan, Do, Study, and Act (PDSA) cycles.

Learning Objectives

By the end of this course, you will:

  • Be familiar with the following guidelines and recommendations:
  • Recognize how the key activities identified in this course contribute to high-quality, ongoing growth surveillance of all patients and care of patients identified with linear growth failure.
  • Be able to implement ideas for change to help you do the following:
  • Measure and improve care delivery and processes for the above key activities by doing the following:
  • Evidence-based clinical practice guideline on linear growth measurement of children. The National Guideline Clearinghouse (NCG) Rockville, MD; Agency for Healthcare Research and Quality (AHRQ).
  • AAP Bright Futures Recommendations for Preventive Pediatric Health Care. Bright Futures / American Academy of Pediatrics.
  • Performing Preventive Service: Physical Examination. (Sexual Maturity Stages pp. 79-85) Hagan JF, Shaw JS, Duncan P, Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents.
  • Consensus Statement on the Diagnosis and Treatment of Children with Idiopathic Short Stature: A Summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop.
  • For the pediatrician, demonstrate regular and accurate measurement and plotting of growth at every health supervision visit, and ideally during all visits to provide a complete record of growth.
  • For the endocrinologist, demonstrate regular and accurate measurement and plotting of growth at every visit to monitor growth care.
  • Assess pubertal development at every health supervision visit.
  • Share the child’s growth pattern with the family at every health supervision visit.
  • Identify and address patient/family’s growth or development concerns.
  • Provide necessary education and support when a growth or pubertal development concern is raised or a psychosocial issue is identified.
  • Create (endocrinologist) or obtain (pediatrician) a written care plan for patients with abnormal growth that is developed in partnership with the patient and family, shared with growth team members, and includes timely health status updates.
  • Establish processes for regular, ongoing communication among growth care team members that identifies team members, facilitates effective referrals, and provides timely updates on the patient’s care plan and health status.
  • Collect and analyze baseline data to establish a starting point for improvement.
  • Identify one or more performance gaps in key activities of growth surveillance/care.
  • Create an improvement plan for closing identified performance gap(s) and document the improvement idea to be tested:

AIM: What are we trying to improve or accomplish?

MEASURES: How will we know that a change made is an improvement?

CHANGES: What changes can we make that will result in improvement?

  • Test ideas quickly on a small scale to determine if the changes lead to improvement.
  • Collect and analyze follow-up data to measure the results of the test. (A minimum of two follow-up data collection cycles are necessary for course completion and maintenance of certification recognition).
  • Determine how to sustain successful changes and how to systematically integrate them into the culture, processes, and workflow of your practice.
  • Create additional improvement plans and repeat PDSA cycles until you reach the maximum potential of providing optimal growth surveillance/care in your practice.


Disclosure of Financial Relationships and Resolution of Conflicts of Interest for AAP

CME Activities

The AAP CME program aims to develop, maintain, and improve the competence, skills, and

professional performance of pediatricians and pediatric healthcare professionals by providing

quality, relevant, accessible, and effective educational experiences that address gaps in

professional practice. The AAP CME program strives to meet participants' educational needs

and support their life-long learning with a goal of improving care for children and families. (AAP

CME Program Mission Statement, January 2013)

 

The AAP recognizes that there are a variety of financial relationships between individuals and

commercial interests that require review to identify possible conflicts of interest in a CME

activity. The “AAP Policy on Disclosure of Financial Relationships and Resolution of Conflicts of

Interest for AAP CME Activities” is designed to ensure quality, objective, balanced, and

scientifically rigorous AAP sponsored or jointly sponsored Continuing Medical Education (CME)

activities by identifying and resolving all potential conflicts of interest prior to the confirmation of

service of those in a position to influence and/or control CME content.

 

All AAP CME activities will strictly adhere to the Accreditation Council for Continuing Medical

Education (ACCME) Standards for Commercial Support: Standards to Ensure the

Independence of CME Activities. In accordance with these Standards, the following decisions

will be made free of the control of a commercial interest: identification of CME needs,

determination of educational objectives, selection and presentation of content, selection of all

persons and organizations that will be in a position to control the content, selection of

educational methods, and evaluation of the CME activity (ACCME Standard 1.1).

 

The purpose of this policy and its associated procedures is to ensure all potential conflicts of

interest are identified and mechanisms to resolve them prior to the CME activity are

implemented in ways that are consistent with the public good.

 

The content of this CME activity does not necessarily reflect the views or policies of the AAP.

 

Disclosure of Financial Relationships

 

All individuals in a position to influence and/or control the content of AAP CME activities are

required to disclose to the AAP and subsequently to learners that the individual either has no

relevant financial relationships or any financial relationships with the manufacturer(s) of any

commercial product(s) and/or provider(s) of commercial services discussed in CME activities.

*Commercial interest is defined as any entity producing, marketing, re-selling, or distributing

health care goods or services consumed by, or used on, patients.

 

 

Name/Role

Relevant Financial Relationship

(Please indicate Yes, or No)

Name of Commercial Interest(s)*

Please list name(s) of entity AND Nature of Relevant Financial Relationship(s)

(Please list: Research Grant, Speaker’s Bureau, Stock/Bonds excluding mutual funds, Consultant, Other - identify)

Disclosure of Off-Label (Unapproved)/

Investigational Uses of Products

 

AAP CME faculty are required to disclose to the AAP and to learners when they plan to discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or “off-label” use of an approved device or pharmaceutical.

(Do intend to discuss or Do not intend to discuss)

Kathleen Bethin, MD, PhD, FAAP

Course Faculty

No

None

Do not intend to discuss

Ellen Lancon Connor, MD, FAAP

Course Faculty

No

None

Do not intend to discuss

Teresa Duryea, MD, FAAP 

Course Faculty

Yes

Royalties:

   UpToDate

Do not intend to discuss

Jeffrey Grill, MD, FAAP

Course Faculty

No

None

Do not intend to discuss

Quentin Van Meter, MD, FAAP

Course Faculty

Yes

Speakers' Bureau:

Lilly Pharmaceuticals

Novo Nordisk

Pfizer

Endo Pharmaceuticals

Genentech

Research Grant:

Ipsen/Tercica

Do not intend to discuss

Kupper A Wintergerst, MD, FAAP

Course Faculty

Yes

Honorarium: (Received for lecture given)

Pfizer, Inc

Genetech

Do not intend to discuss

Mark Danney, MD, FAAP

Course Reviewer

No

None

Do not intend to discuss

Laura Laskosz, MPH

AAP Staff

No

None

Do not intend to discuss

Lori Morawski, MPH, CHES

AAP Staff

No

None

Do not intend to discuss

Linda O’Brien

AAP Staff

No

None

Do not intend to discuss

Teri Blommaert

Instructional Design Consultant

No

None

Do not intend to discuss

Diane Guerriero

Instructional Design Consultant

No

None

Do not intend to discuss

Robert Perelman, MD, FAAP

AAP Staff

No
 None  Do not intent to discuss

 

Commercial Supporters

The EQIPP: Growth Surveillance and Linear Growth Failure course was produced by the American Academy of Pediatrics.  This course is supported by an educational grant from Novo Nordisk Inc.

Product-Specific Advertising

No product-specific advertising of any type appears in this activity.  No links to product websites appear in this activity.

List of Principal Faculty and Credentials

Kathleen Bethin, MD, PhD, FAAP

Ellen Lancon Connor, MD, FAAP

Teresa Duryea, MD, FAAP 

Jeffrey Grill, MD, FAAP

Quentin Van Meter, MD, FAAP

Kupper A Wintergerst, MD, FAAP

AAP Staff:

Lori Morawski, MPH, CHES

Linda O’Brien

Laura Laskosz, MPH

Instructional Designer:

Diane Guerriero

Teri Blommaert

Name of Medium or Combination of Media Used

Internet course

Method of physician participation in the learning process

The EQIPP: Growth Surveillance and Linear Growth Failure course requires you to do some work online and some offline. The online work involves reviewing the content presentation, researching linked information, and participating in guided activities. The offline work includes the performance improvement activities you will do within your own practice to improve key activities in your practice.

Please note:  CME credit is only awarded to learners who enter and analyze data.  Using sample data provided by EQIPP will exclude learners from receiving AMA Category 1 Credit™ for the performance improvement activity portion of the course.

Estimated time to complete the educational activity

You may progress through the course at a pace that is comfortable for you, taking into consideration the demands of your practice. But it is important to establish a goal for completion. The amount of time you are likely to spend per clinical content area can vary depending on if you pursue additional links for more learning. You may also want to consider some elapsed time between sections to “catch your breath.”

Completion requirements for the Performance Improvement activity include:

  1. Enter baseline data and analyze your results.
  2. Create an improvement plan that has a minimum of 1 aim statement.
  3. Document a minimum of 1 idea for change
  4. Enter data for a minimum of two follow up data sets and analyze your results.
  5. Submit a course evaluation.

Generally speaking, the course can be completed within 4-8 months, depending on the number of improvement cycles you make to reach the goals you have set for your practice.

American Board of Pediatrics Maintenance of Certification Requirements

The American Board of Pediatrics requires two data cycles to meet MOC requirements.  A data cycle consists of Baseline data entry, an improvement plan, an idea for change, and followup data entry.  

Dates of Original Release and Most Recent Review or Revision

This course was launched on February 25, 2014.

Termination Date

This course will remain online until February 25, 2017. It will no longer be certified for credit after February 25, 2017.

List of Hardware/Software Requirements

Recommended browsers:

  • Internet Explorer 7.0 and above
  • Firefox 3.0 and above
  • Safari 5.0 and above

Recommended browser settings:

  • JavaScript enabled
  • Cookies enabled
  • SSL 2.0 & SSL 3.0 enabled
  • Flash Player Plug-in (version 7.0 +)
  • Adobe Reader Plug-in (version 6.0 +)

Provider Contact information

If you have questions about this course or encounter technical problems, please contact PediaLink at [email protected].  Subject: EQIPP: Growth Surveillance and Linear Growth Failure


Privacy and Confidentiality Statement

At the American Academy of Pediatrics, we take the issue of privacy very seriously. We do not sell, distribute, barter, or transfer personally identifiable information obtained from a user to a third party. Any information collected on the Web site is only used for the purpose stated.

The AAP list is only for important Academy communications, and your e-mail address will not be sold or provided to third parties. You will not receive advertising or promotional material on this list.

The American Academy of Pediatrics may use "cookie" technology to obtain non-personal information from its online visitors. We do not extract personal information in this process nor do we provide this information to third parties. We also do not contact you based on information in your cookie file.

The American Academy of Pediatrics has taken steps to make all information received from our online visitors as secure as possible against unauthorized access and use. All information is protected by our security measures, which are periodically reviewed.

Copyright© 2014 by the American Academy of Pediatrics All rights reserved.